NCT04937452View on ClinicalTrials.gov

Dopaminergic Therapy for Frontotemporal Dementia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

April 1, 2024

Conditions
Frontotemporal DementiaDementiaAphasia, Primary ProgressivePick Disease of the BrainBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersNeurodegenerative DiseasesFrontotemporal Lobar DegenerationTDP-43 ProteinopathiesProteostasis DeficienciesMetabolic DiseaseAphasiaSpeech DisordersLanguage DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic Manifestations
Interventions
DRUG

Rotigotine 4Mg/24Hrs Patch

Rotigotine 4 mg/24Hrs administration for 24 weeks

DRUG

Rotigotine 6Mg/24Hrs Patch

Rotigotine 6 mg/24Hrs administration for 24 weeks

DRUG

Placebo

Placebo administration for 24 weeks

Trial Locations (3)

00179

Giacomo Koch, Rome

Santa Lucia Foundation, Rome

Unknown

Department of Neurology, University of Brescia, Brescia

All Listed Sponsors
collaborator

Alzheimer's Drug Discovery Foundation

OTHER

lead

I.R.C.C.S. Fondazione Santa Lucia

OTHER